Company news

Candel Therapeutics, Inc. news in 2024

Candel Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

December 15, 2024

Candel Therapeutics Announces $80 Million Proposed Public Offering

December 11, 2024

Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

December 10, 2024

Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

November 13, 2024

Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma

November 4, 2024

Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting

October 3, 2024

Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

August 12, 2024

Candel Therapeutics to Join Russell 3000® Index

June 10, 2024

Candel Therapeutics’ (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers

June 6, 2024

Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer

June 2, 2024

FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma

May 29, 2024

Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting

May 22, 2024

Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

May 13, 2024

Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

April 24, 2024

Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer

April 10, 2024

Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors

April 8, 2024

Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

April 3, 2024

Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights

March 27, 2024

Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma

March 27, 2024

Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate

March 4, 2024

Moving Fast: Candel’s (NASDAQ: CADL) CAN-3110 Granted FDA Fast Track Designation For Recurrent High-Grade Glioma Following Fast Track Designation For CAN-2409 In Pancreatic Cancer

February 27, 2024

Candel Therapeutics Sets Stage For Success With Cancer-Fighting Immunotherapies

February 14, 2024

CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma

February 12, 2024

Decks in 2024